Clinical Trial Update: Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update indicating that QRX003 Lotion is being studied in Phase 2/3 for Netherton Syndrome and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Netherton Syndrome

Drugs mentioned

• QRX003 Lotion

Snippet

Sponsor: Quoin Pharmaceuticals | Conditions: Netherton Syndrome | Phase 2, Phase 3 | Status: RECRUITING